Drug Type Monoclonal antibody |
Synonyms Anti-CXCR2 mAb(Corvus Pharmaceuticals), CPI 182, CPI-182 |
Target |
Mechanism CXCR2 antagonists(C-X-C motif chemokine receptor 2 antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Dermatitis, Atopic | Preclinical | US | 21 Dec 2020 | |
Dermatitis, Atopic | Preclinical | AU | 21 Dec 2020 | |
Rheumatoid Arthritis | Preclinical | US | 21 Dec 2020 | |
Rheumatoid Arthritis | Preclinical | AU | 21 Dec 2020 | |
Inflammation | Preclinical | US | - |